People · Operator
Named in public records as an officer, director or promoter · active 2012–2022 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Escient Pharmaceuticals Inc | — | Biotechnology | Series C | $108.8M | $994.9M | 2018 |
| Receptos, Inc. (f.k.a. Receptor Pharmaceuticals Inc.) | — | Pharmaceuticals | Series A | $30.5M | $334.7M | 2012 |
| StemoniX, Inc. | — | Biotechnology | Series A | $14.6M | $3.6M | 2016 |
Marcus Boehm at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Marcus Boehm on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 1 | 22 |
| Kristina Burow | 1 | 16 |
| Andrew Schwab | 1 | 16 |
| Amir Nashat | 1 | 14 |
| Robert Nelson | 1 | 7 |
| Peter Hirth | 1 | 7 |
| Doug Cole | 1 | 6 |
| Jason Hafler | 1 | 6 |
| Sheila Gujrathi | 1 | 5 |
| Faheem Hasnain | 1 | 5 |
| PAUL Grayson | 1 | 5 |
| Yung-Ping Yeh | 1 | 4 |
| William Rastetter | 1 | 4 |
| Kevin Raidy | 1 | 4 |
| Kathleen Sereda Glaub | 1 | 3 |
| Raymond Stevens | 1 | 3 |
| James Schmidt | 1 | 3 |
| Robert Tjian | 1 | 3 |
| Kathleen Glaub | 1 | 3 |
| Paul Hansen | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.